AXDX
Accelerate Diagnostics Inc

2,108
Mkt Cap
$176,500.00
Volume
666,665.00
52W High
$0.049
52W Low
$0.0038
PE Ratio
0.00
AXDX Fundamentals
Price
$0.035
Prev Close
$0.088
Open
$0.0795
50D MA
$0.0096
Beta
0.00
Avg. Volume
100,641.95
EPS (Annual)
-$2.15
P/B
-0.00
Rev/Employee
$109,327.10
Loading...
Loading...
News
all
press releases
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results PR...
PR Newswire·10mo ago
News Placeholder
More News
News Placeholder
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results
Accelerate Diagnostics Reports Third Quarter 2024 Financial Results Accelerate Diagnostics Reports Third Quarter 2024 Financial Results PR Newswire TUCSON, Ariz., Nov. 7, 2024 TUCSON,Ariz., Nov. 7...
PR Newswire·1y ago
News Placeholder
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc System
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc System Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc System PR Newswire TUCSON, Ariz., Sept. 30, 2024 An...
PR Newswire·1y ago
News Placeholder
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results Accelerate Diagnostics Reports Second Quarter 2024 Financial Results PR Newswire TUCSON, Ariz., Aug. 8, 2024 TUCSON, Ariz., Aug...
PR Newswire·1y ago
News Placeholder
Accelerate Diagnostics Announces a Successful Completion of its WAVE Pre-Clinical Trial
Accelerate Diagnostics Announces a Successful Completion of its WAVE Pre-Clinical Trial Accelerate Diagnostics Announces a Successful Completion of its WAVE Pre-Clinical Trial PR Newswire TUCSON...
PR Newswire·1y ago
News Placeholder
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results PR Newswire TUCSON, Ariz., Aug. 8, 2024 TUCSON...
PR Newswire·1y ago
News Placeholder
Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results
Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results PR Newswire TUCSON, Ariz., May 8, 2024...
PR Newswire·2y ago
News Placeholder
Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results.
Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results. Accelerate Diagnostics Scheduled Call to Review 2024 First Quarter Results. PR Newswire TUCSON, Ariz., May 2, 2024 TUCSON...
PR Newswire·2y ago
News Placeholder
Insider Selling: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) CEO Sells $13,980.56 in Stock
Accelerate Diagnostics, Inc. (NASDAQ:AXDX - Get Free Report) CEO Jack Phillips sold 15,887 shares of the company's stock in a transaction on Thursday, April 4th. The stock was sold at an average...
Zolmax·2y ago
News Placeholder
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com
Analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX - Get Free Report) in a research note issued to investors on Thursday. The brokerage set a "hold" rating on...
Zolmax·2y ago

Latest AXDX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.